What insurance policy changes affect code O16.9?

There are 6 tracked policy changes affecting code O16.9, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code O16.9?

Payers that have issued tracked updates for code O16.9 include: Aetna.

How do I get notified when code O16.9 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code O16.9. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code O16.9?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

O16.9 Insurance Policy Changes

ICD-10 O16.9 is officially defined as "Unspecified maternal hypertension, unspecified trimester." code O16.9 is referenced in 6 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code O16.9 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Effective May 31, 2026High impact
Remote Physiologic Monitoring (RPM) (CPB 1093, reviewed 2026-05-31)
Aetna has clarified its Remote Physiologic Monitoring (RPM) coverage policy (CPB 1093, effective 2026-05-31) establishing strict medical necessity criteria for three conditions: heart failure, hypertension, and diabetes. RPM is now only covered when using FDA-approved devices with automatic data transmission, documented patient consent, provider ordering/supervision, and clinical impact on treatment plans. Coverage is limited to one episode per patient per condition per provider per month. Billing teams must verify all criteria are met before submitting claims and ensure documentation supports medical necessity.
Aetna · Identified Oct 26, 2026Medium impact
Remote Physiologic Monitoring (RPM) (CPB 1093, reviewed 2026-06-01)
Aetna Clinical Policy Bulletin 1093 on remote physiologic monitoring (RPM), reviewed 2026-06-01, considers RPM medically necessary when all listed criteria are met, including a member with heart failure, hypertension or diabetes, an FDA-approved or cleared device capable of automatic data transmission, and documentation of patient consent in the medical record. The policy considers RPM experimental, investigational or unproven for conditions other than those listed, and for RPM using devices not approved or cleared by the FDA, and it states that coverage is limited to one episode of RPM per patient per condition per provider per month.
Aetna · Identified Oct 2, 2026Medium impact
Cardiovascular Monitoring Equipment for Home Use: Pulse, Blood Pressure, Telemonitors, and Pacemaker Monitors (CPB 0548, reviewed 2026-08-21)
Aetna considers validated home blood pressure monitors medically necessary as an alternative to ambulatory blood pressure monitoring to confirm hypertension in members age 18 and older with office readings greater than 140 systolic or 90 diastolic. Validated blood pressure monitors are considered medically necessary for members receiving hemodialysis or peritoneal dialysis in the home, and validated blood pressure cuffs are considered medically necessary durable medical equipment for members with hypertension. Self-contained pacemaker monitors, including audible and visible signal monitors, digital electronic monitors, and a specialized telephone attachment for trans-telephonic transmission of results, are considered medically necessary for members with cardiac pacemakers. Automated oscillometer serial blood pressure monitors for home use, AngelMed Guardian, CardioMEMS pillow and components, home and implantable congestive heart failure monitors, implantable inferior vena cava sensors, implantable wireless pulmonary artery pressure monitors for heart failure, Zoll Heart Failure and Arrhythmia Management System, bioelectrical impedance analysis, and non-invasive central blood pressure assessment with SphygmoCor are considered experimental, investigational, or unproven. Pulse tachometers do not meet Aetna's definition of covered durable medical equipment.
Aetna · Identified Aug 19, 2026Medium impact
Hypertensive Disorders of Pregnancy (CPB 0368, reviewed 2026-05-22)
Aetna considers obstetrical hypertension programs experimental, investigational, or unproven because they have not been proven to be more effective than member self-management performed in concert with supervision by an obstetrician in reducing fetal or maternal morbidity and mortality. Aetna also considers PEPredictDx, a test for identifying women at high risk for pre-eclampsia, experimental, investigational, or unproven. CPT code 0390U and HCPCS codes S9211, S9212, and S9213 (home management of gestational hypertension, postpartum hypertension, and preeclampsia) are listed as not covered for the indications in this policy, and several ICD-10 codes for hypertension complicating pregnancy, gestational hypertension, preeclampsia, and eclampsia are also listed as not covered.
Aetna · Identified Aug 17, 2026Medium impact
Hepatitis Screening (CPB 0835, reviewed 2025-12-09)
Aetna considers hepatitis B screening medically necessary for listed groups, including people on hemodialysis, blood or organ donors, pregnant women, people with HIV, injection drug users, men who have sex with men, and people born in regions with a 2% or higher HBV prevalence. Hepatitis C screening is medically necessary for listed groups, and one-time HCV testing without prior risk assessment is medically necessary for adults aged 18 years and older. Hepatitis D screening is medically necessary for people with HBsAg-positive hepatitis B infection and significant risk factors, while hepatitis E screening in the peri-transplant period is experimental, investigational, or unproven.
Aetna · Identified Aug 17, 2026Medium impact
ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP) (CPB 0780, reviewed 2026-04-27)
Aetna considers the ADAMTS13 assay medically necessary for assessing prognosis in persons with thrombotic thrombocytopenic purpura (TTP), and for distinguishing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA, also called transplant-associated TMA) from TTP in persons with overlapping features when the test will be used to inform treatment. Aetna considers the assay experimental, investigational, or unproven for the uses it lists because of insufficient evidence, including sepsis-associated thrombotic microangiopathy, hemolytic uremic syndrome, acute myelogenous leukemia, colorectal cancer survival, COVID-19, cerebral infarction, and ADAMTS13 mutation testing for non-cirrhotic portal hypertension.

Watch O16.9

Get one email when a payer policy names O16.9, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Remote Physiologic Monitoring (RPM) (CPB 1093, reviewed 2026-05-31)

Remote Physiologic Monitoring (RPM) (CPB 1093, reviewed 2026-06-01)

Cardiovascular Monitoring Equipment for Home Use: Pulse, Blood Pressure, Telemonitors, and Pacemaker Monitors (CPB 0548, reviewed 2026-08-21)

Hypertensive Disorders of Pregnancy (CPB 0368, reviewed 2026-05-22)

Hepatitis Screening (CPB 0835, reviewed 2025-12-09)

ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP) (CPB 0780, reviewed 2026-04-27)

What insurance policy changes affect code O16.9?

Which payers have updated policy for code O16.9?

How do I get notified when code O16.9 policy changes?

Why do payers change policies for code O16.9?